7Q5V

HIF PROLYL HYDROXYLASE 2 (PHD2/EGLN1) IN COMPLEX WITH N-OXALYLGLYCINE (NOG) AND HIF-2 ALPHA CODD (523-542)

7Q5V の概要

• エントリーDOI: 10.2210/pdb7q5v/pdb
• 分子名称: Egl nine homolog 1, Endothelial PAS domain-containing protein 1, MANGANESE (II) ION, ... (10 entities in total)
• 機能のキーワード: phd2, hif-2alpha, complex, oxidoreductase, hypoxia
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 29205.05

構造登録者

Figg Jr, W.D.,McDonough, M.A.,Chowdhury, R.,Nakashima, Y.,Schofield, C.J. (登録日: 2021-11-04, 公開日: 2022-11-16, 最終更新日: 2024-11-13)

主引用文献

Figg Jr., W.D.,Fiorini, G.,Chowdhury, R.,Nakashima, Y.,Tumber, A.,McDonough, M.A.,Schofield, C.J.
Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2 alpha to prolyl hydroxylase domain 2.
Proteins, 91:1510-1524, 2023

PubMed Abstract: The hypoxia-inducible factor (HIF) prolyl-hydroxylases (human PHD1-3) catalyze prolyl hydroxylation in oxygen-dependent degradation (ODD) domains of HIFα isoforms, modifications that signal for HIFα proteasomal degradation in an oxygen-dependent manner. PHD inhibitors are used for treatment of anemia in kidney disease. Increased erythropoietin (EPO) in patients with familial/idiopathic erythrocytosis and pulmonary hypertension is associated with mutations in EGLN1 (PHD2) and EPAS1 (HIF2α); a drug inhibiting HIF2α activity is used for clear cell renal cell carcinoma (ccRCC) treatment. We report crystal structures of PHD2 complexed with the C-terminal HIF2α-ODD in the presence of its 2-oxoglutarate cosubstrate or N-oxalylglycine inhibitor. Combined with the reported PHD2.HIFα-ODD structures and biochemical studies, the results inform on the different PHD.HIFα-ODD binding modes and the potential effects of clinically observed mutations in HIFα and PHD2 genes. They may help enable new therapeutic avenues, including PHD isoform-selective inhibitors and sequestration of HIF2α by the PHDs for ccRCC treatment.

PubMed: 37449559
DOI: 10.1002/prot.26541

実験手法

X-RAY DIFFRACTION (1.17 Å)